Orakl Oncology combines data and biology to bring new drugs to cancer patients
Cancer rates are increasing among young adults, yet most new drugs fail in clinical trials due to flawed trial designs, according to entrepreneur Fanny Jaulin.
MAIN POINTS
- Cancer incidence is rising, especially in younger adults.
- Most new drug compounds do not succeed in clinical trials.
- Fanny Jaulin attributes drug trial failures to poor clinical trial design.
- A drug's failure in trials doesn't necessarily indicate its ineffectiveness.
TAKEAWAYS
- There is a growing need for effective cancer treatments for younger populations.
- Improving clinical trial designs could enhance drug approval success rates.
- Re-evaluating trial methodologies may uncover effective drugs previously deemed unsuccessful.
- Entrepreneurs like Fanny Jaulin are advocating for changes in the clinical trial process.